# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001654954-25-012888
**Filing Date:** 2025-11
**Character Count:** 6347
**Document Hash:** 3aeef693725ab8a9e93a68f379140f17
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-012888.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001654954-25-012888

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251112

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 251471371

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **Form 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

 **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2025

Commission File Number 001-15170

 **GSK plc**

(Translation of registrant's name into English)

 **79 New Oxford Street, London, WC1A 1DG**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

 **BLOCK LISTING SIX MONTHLY RETURN** 

 **Date:** 12 November 2025

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name of *applicant*: | Name of *applicant*: | GSK plc | GSK plc | GSK plc |
| Name of scheme: | Name of scheme: | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan |
| Period of return:<br>| From:<br>| 1 May 2025<br>| To:<br>| 31 October 2025<br>|
| Balance of unallotted securities under scheme(s) from previous return: | Balance of unallotted securities under scheme(s) from previous return: | 115518 | 115518 | 115518 |
| <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | 0 | 0 |
| <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 0 | 0 | 0 |
| <u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period: | <u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period: | 115518 | 115518 | 115518 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name of *applicant*: | Name of *applicant*: | GSK plc | GSK plc | GSK plc |
| Name of scheme: | Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | GlaxoSmithKline plc Share Save Plan 2012 | GlaxoSmithKline plc Share Save Plan 2012 |
| Period of return:<br>| From:<br>| 1 May 2025<br>| To:<br>| 31 October 2025<br>|
| Balance of unallotted securities under scheme(s) from previous return: | Balance of unallotted securities under scheme(s) from previous return: | 270315 | 270315 | 270315 |
| <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | 0 | 0 |
| <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 134547 | 134547 | 134547 |
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 135768 | 135768 | 135768 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Name of *applicant*: | Name of *applicant*: | GSK plc | GSK plc | GSK plc |
| Name of scheme: | Name of scheme: | GlaxoSmithKline plc Share Save Plan 2022 | GlaxoSmithKline plc Share Save Plan 2022 | GlaxoSmithKline plc Share Save Plan 2022 |
| Period of return:<br>| From:<br>| 1 May 2025<br>| To:<br>| 31 October 2025<br>|
| Balance of unallotted securities under scheme(s) from previous return: | Balance of unallotted securities under scheme(s) from previous return: | 951791 | 951791 | 951791 |
| <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | <u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | 0 | 0 |
| <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | <u>Less:</u> Number of *securities* issued/allotted under scheme(s) during period (see UKLR 20.6.7G): | 47674 | 47674 | 47674 |
| <u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period: | <u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period: | 904117 | 904117 | 904117 |

---

<u> Name of contact: </u> Victoria Whyte <br> <u> Telephone number of contact: </u> <u> 020 8047 5000 </u>

 **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

---

| | |
|:---|:---|
|  | **GSK plc** |
|  | (Registrant) |
| Date: November 12, 2025 |  |
|  | By:/s/ VICTORIA WHYTE<br> -------------------------- |
|  | Victoria Whyte |
|  | Authorised Signatory for and on |
|  | behalf of GSK plc |

---